All articles
GLP-1s for Pre-diabetes: Can You Prevent Type II Diabetes?
Reading time:
11 min
Weight loss
Get expert guidance and a personalized care plan designed around you.
Tirzepatide Evidence: SURMOUNT-1 Three-Year Results
The most dramatic diabetes prevention data comes from the SURMOUNT-1 trial three-year extension in participants with prediabetes, published in the New England Journal of Medicine in November 2024.
This analysis focused on 1,032 participants from SURMOUNT-1 who had both obesity and prediabetes at the start of the trial. Participants were randomized to receive tirzepatide at doses of 5 mg, 10 mg, or 15 mg weekly, or placebo, for 176 weeks (over three years), followed by a 17-week off-treatment period.
The results were striking. After 176 weeks of treatment, only 1.3% of participants taking tirzepatide (pooled across all doses) progressed to type 2 diabetes, compared to 13.3% taking placebo. This represents a 94% reduction in the risk of developing diabetes. More than 90% of participants on tirzepatide had normal A1C levels at 176 weeks, compared to 59% of placebo-treated participants.
Even after stopping medication for 17 weeks, only 2.4% of those who had received tirzepatide had developed diabetes, compared to 13.7% of the placebo group. This suggests some durability of effect even after discontinuation, though the protective benefit was stronger during active treatment.
The number needed to treat was nine, meaning that for every nine people treated with tirzepatide, one case of diabetes would be prevented. This represents highly effective prevention.
Weight loss with tirzepatide was substantial and sustained. Participants on the 15 mg dose achieved an average weight reduction of 22.9% at 176 weeks. This degree of weight loss contributed to the metabolic improvements, though tirzepatide’s effects on glucose metabolism extend beyond weight loss through direct effects on insulin sensitivity and beta cell function.
At 72 weeks, more than 95% of participants with prediabetes who received tirzepatide had converted to normoglycemia (A1C below 5.7%), compared to 62% in the placebo group.
How GLP-1 Medications Prevent Diabetes Progression
Understanding the mechanisms helps explain why these medications are so effective for diabetes prevention beyond their weight loss effects.
GLP-1 receptor agonists improve insulin sensitivity, meaning your cells respond better to insulin. This reduces the demand on your pancreas to produce excessive insulin. The medications enhance insulin secretion from pancreatic beta cells in response to glucose. This glucose-dependent mechanism means insulin is released when blood sugar is elevated but not when it is normal, reducing hypoglycemia risk.
GLP-1 agonists suppress glucagon, a hormone that raises blood sugar. In prediabetes and diabetes, glucagon is often inappropriately elevated, contributing to high blood sugar. Suppressing it helps normalize glucose levels. The medications slow gastric emptying, which means glucose from food enters your bloodstream more gradually rather than causing sharp spikes.
Weight loss from GLP-1 medications independently improves insulin sensitivity and reduces the metabolic stress on beta cells. Adipose tissue (fat tissue) produces inflammatory molecules that worsen insulin resistance. Losing fat mass reduces this inflammation and improves metabolic health.
These combined mechanisms address multiple aspects of the metabolic dysfunction in prediabetes simultaneously, which explains why the medications are more effective than lifestyle intervention alone in clinical trials.
Comparing Approaches: Medication Versus Lifestyle Alone
The clinical trial data allows for comparison between different intervention strategies for preventing diabetes in prediabetes.
Lifestyle intervention alone (as shown in the Diabetes Prevention Program) reduces diabetes progression by approximately 58% over three years. This is meaningful and represents the foundation of treatment. The intervention requires approximately 7% weight loss and 150 minutes per week of moderate physical activity.
Semaglutide 2.4 mg weekly plus lifestyle intervention results in 84% to 85% of people with prediabetes achieving normal blood sugar at 68 weeks based on STEP trial analyses. This substantially exceeds the roughly 48% to 70% seen with placebo plus lifestyle intervention in the same trials.
Tirzepatide at doses of 5 mg to 15 mg weekly plus lifestyle intervention results in 94% reduction in diabetes progression over 176 weeks based on SURMOUNT-1 data. More than 95% achieved normoglycemia at 72 weeks with tirzepatide compared to 62% with placebo.
The medication approaches produce greater weight loss than lifestyle intervention alone. In the STEP trials, semaglutide produced 10% to 17% weight loss over 68 weeks. In SURMOUNT-1, tirzepatide produced 15% to 22.5% weight loss at 72 weeks and sustained weight loss of nearly 23% at 176 weeks with the 15 mg dose. This compares to typical weight loss of 3% to 5% with intensive lifestyle intervention alone.
This does not mean lifestyle changes are unnecessary when using medication. The trials combined medication with lifestyle intervention. The medications work best when paired with healthy eating and physical activity, not as a replacement for these behaviors.
Who Should Consider GLP-1 Medications for Prediabetes?
The decision about whether to use medication for prediabetes involves weighing several factors including your individual diabetes risk, response to lifestyle intervention, other health conditions, and personal preferences.
Medical guidelines generally recommend starting with lifestyle intervention for prediabetes. If you have not yet attempted sustained lifestyle changes (dietary modification and regular physical activity), starting there makes sense for most people. Lifestyle changes provide broad health benefits beyond glucose control and do not involve medication costs or potential side effects.
However, medication might be appropriate earlier for certain individuals. If you have tried intensive lifestyle intervention for several months without achieving adequate weight loss or blood sugar improvement, medication becomes a reasonable addition. If you have multiple diabetes risk factors (family history, previous gestational diabetes, PCOS, significant obesity), more aggressive intervention might be warranted.
If your A1C is in the higher end of the prediabetes range (6.0% or above), you are at greater immediate risk of progression. Earlier medication intervention might be more justified. If you have other obesity-related health conditions that would benefit from significant weight loss (sleep apnea, hypertension, joint problems), GLP-1 medications address multiple conditions simultaneously.
The decision should be made collaboratively with your healthcare provider based on your complete health picture, not based on A1C alone.
At Mochi Health, we provide comprehensive weight management care that includes addressing metabolic health conditions like prediabetes. Our providers can help you understand whether GLP-1 medication is appropriate for your situation, develop a personalized treatment plan, and provide ongoing support. All patients have access to registered dietitian nutritionists who can help you implement the lifestyle changes that work synergistically with medication. Beyond weight management, we offer medications for related health conditions. You can explore treatment options at https://joinmochi.com/medications.
Check Your Eligibility
If you want to learn whether GLP-1 treatment is right for you and receive personalized guidance from providers who understand prediabetes management and diabetes prevention, you can start by completing Mochi’s eligibility questionnaire. Check your eligibility.
References:
Centers for Disease Control and Prevention. (2024). Prediabetes—Your chance to prevent type 2 diabetes. U.S. Department of Health and Human Services. https://www.cdc.gov/diabetes/prevention-type-2/prediabetes-prevent-type-2.html
Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., Jódar, E., Kandler, K., Rigas, G., Wadden, T. A., Wharton, S., Jastreboff, A. M., & STEP 5 Study Group. (2022). Two-year effects of semaglutide in adults with overweight or obesity: The STEP 5 trial. Nature Medicine, 28(10), 2083-2091. https://doi.org/10.1038/s41591-022-02026-4
Garvey, W. T., Frias, J. P., Jastreboff, A. M., le Roux, C. W., Sattar, N., Aizenberg, D., Mao, H., Zhang, S., Ahmad, N. N., Bunck, M. C., Benabbad, I., Zhang, X. M., Hope, K., Haluzík, M., & SURMOUNT-2 Investigators. (2023). Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): A double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. The Lancet, 402(10402), 613-626. https://doi.org/10.1016/S0140-6736(23)01200-X
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., Stefanski, A., & SURMOUNT-1 Investigators. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. https://doi.org/10.1056/NEJMoa2206038
Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., Hartman, M. L., & SURMOUNT-1 Investigators. (2024). Tirzepatide for obesity treatment and diabetes prevention. New England Journal of Medicine, 391(20), 1942-1952. https://doi.org/10.1056/NEJMoa2410819
Knowler, W. C., Barrett-Connor, E., Fowler, S. E., Hamman, R. F., Lachin, J. M., Walker, E. A., Nathan, D. M., & Diabetes Prevention Program Research Group. (2002). Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine, 346(6), 393-403. https://doi.org/10.1056/NEJMoa012512
Perreault, L., Davies, M., Frias, J. P., Laursen, P. N., Lingvay, I., Machineni, S., Varbo, A., Wilding, J. P. H., Wallenstein, S. O. R., & le Roux, C. W. (2023). Changes in glucose metabolism and glycemic status with once-weekly subcutaneous semaglutide 2.4 mg among participants with prediabetes in the STEP program. Diabetes Care, 46(12), 2252-2262. https://doi.org/10.2337/dc23-0556
Rosenstock, J., Lingvay, I., Herman, W. H., Sattar, N., Rothwell, P. M., Bain, S. C., McGuire, D. K., Pratley, R. E., Montanya, E., Brown-Frandsen, K., Aizenberg, D., Reusch, J., Frederich, R., Capehorn, M., Lim, S., Kahn, S. E., Huey, G. Y. Y., Qian, Y., Chow, K. F., … Buse, J. B. (2024). Efficacy and safety of once-weekly semaglutide 2.4 mg versus placebo in people with obesity and prediabetes (STEP 10): A randomised, double-blind, placebo-controlled, multicentre phase 3 trial. The Lancet Diabetes & Endocrinology, 12(8), 545-557. https://doi.org/10.1016/S2213-8587(24)00182-7
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., Salminen, V., Uusitupa, M., & Finnish Diabetes Prevention Study Group. (2001). Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine, 344(18), 1343-1350. https://doi.org/10.1056/NEJM200105033441801
This article is for educational purposes only and should not be considered medical advice. Consult with healthcare providers about whether GLP-1 medications are appropriate for your individual health needs and circumstances.
Share this post
Weight loss
More articles
Read next
For iOS & Android
